伊布替尼联合奥妥珠单抗治疗复发或难治性慢性淋巴细胞白血病的1b期研究
本研究在复发或难治性慢性淋巴细胞白血病患者中评估伊布替尼联合奥妥珠单抗的3种给药顺序的耐受性及总体安全性和疗效。52例患者初始按1:1:1随机分组,观察不同顺序的输注相关反应,仅后两组扩展。最佳总缓解率为96%(40%完全缓解,56%部分缓解),中位随访41.5个月时4年无进展生存率和总生存率分别为74%和93%。
要点
- 最佳总缓解率96%,其中完全缓解40%、部分缓解56%。
- 外周血和骨髓不可测微小残留病的最佳率分别为27%和19%。
- 中位随访41.5个月,4年无进展生存率和总生存率分别为74%和93%。
核心结论
- 伊布替尼联合奥妥珠单抗在复发或难治性慢性淋巴细胞白血病中高度有效,安全性可控,支持进一步研究该类型方案。
研究设计与样本
- 1b期研究,52例复发或难治性慢性淋巴细胞白血病患者初始按1:1:1随机接受3种给药顺序:奥妥珠单抗先于伊布替尼1个月、伊布替尼先于奥妥珠单抗1个月、或两药同时开始。
- 第一种顺序观察到更高的输注相关反应率,仅后两组队列扩展。
主要发现
- 4级血液学毒性不常见;值得注意的全级别非血液学毒性包括瘀伤(58%)、高血压(46%)、关节痛(38%)、腹泻(37%)、转氨酶升高(35%)、心房颤动(21%)和严重感染(17%)。
- 最佳总缓解率为96%(包括40%完全缓解和56%部分缓解)。
- 外周血和骨髓不可测微小残留病的最佳率分别为27%和19%。
- 中位随访41.5个月,4年无进展生存率和总生存率分别为74%和93%。
- 相关研究显示血清CCL4和CXCL13水平与临床缓解相关,BH3谱分析显示治疗中患者CLL细胞的BCL-2和BCL-xL依赖性增加。
关键数值与推荐
- 最佳总缓解率96%(完全缓解40%,部分缓解56%)。
- 外周血不可测微小残留病最佳率27%,骨髓19%。
- 中位随访41.5个月,4年无进展生存率74%,总生存率93%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated ibrutinib plus obinutuzumab in relapsed/refractory CLL, evaluating tolerability of 3 sequencing regimens as well as overall safety and efficacy. Fifty-two patients were initially randomized 1:1:1 to receive either obinutuzumab 1 month before ibrutinib initiation, ibrutinib 1 month prior to obinutuzumab initiation, or to start both drugs concomitantly. Higher rates of infusion-related reactions were observed with the first sequence, and only the latter 2 cohorts were expanded. Grade 4 hematologic toxicity was uncommon, and notable all-grade non-hematologic toxicities included bruising (58%), hypertension (46%), arthralgia (38%), diarrhea (37%), transaminitis (35%), atrial fibrillation (21%), and serious infection (17%). Best overall response rate was 96% (including 40% CR and 56% PR). Best rates of undetectable minimal residual disease in peripheral blood and bone marrow were 27% and 19%, respectively. With a median follow-up of 41.5 months, four-year progression-free and overall survival rates are 74% and 93%, respectively. Correlative studies demonstrated that serum CCL4 and CXCL13 levels were associated with clinical response, and BH3 profiling revealed increased BCL-2 and BCL-xL dependence in CLL cells from patients on treatment. Overall, ibrutinib plus obinutuzumab was highly active, with a manageable safety profile, supporting further investigation of this type of approach in relapsed/refractory CLL.
引用
- Ryan CE, Brander DM, Barr PM, et al. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2023. PMID: 36717653. doi:10.1038/s41375-023-01830-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。